While combined therapy has been widely adopted as first-line in HER2-positive metastatic G/GEJ adenocarcinoma, these updated findings further solidify and position pembrolizumab in combination with trastuzumab and chemotherapy as a standard of care for this patient population. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.